Leadership Changes at Lykos Therapeutics
Lykos Therapeutics has made significant updates to its executive leadership team. The company, which is focused on revolutionizing mental healthcare, will see its founding leader, Amy Emerson, step down from her position as Chief Executive Officer (CEO). Michael Mullette, who has been serving as the Chief Operating Officer (COO), will take over as interim CEO, bringing a wealth of experience from his extensive career in the pharmaceutical sector.
Introducing Michael Mullette as Interim CEO
Michael Mullette, who has over twenty years of experience in various roles within the pharmaceutical industry, is stepping into the interim CEO role at Lykos. His background includes managing critical operations at Moderna during the rollout of the COVID-19 vaccine, as well as holding leadership positions at Sanofi across different countries. Jeff George, the Chairman of the Lykos Board of Directors, highlighted Mullette's qualifications, stating, "Mike is a highly experienced leader with the right background and skills to steer Lykos as we engage with the FDA and work to bring this pioneering treatment to patients in need."
Dr. David Hough Named Chief Medical Officer
Alongside Mullette's appointment, Lykos has also announced Dr. David Hough as its new Chief Medical Officer. Dr. Hough, who recently moved from his role as senior medical advisor, will be responsible for overseeing the clinical development program and the regulatory processes related to the resubmission of midomafetamine. His prior experience includes significant leadership roles at Johnson & Johnson, where he played a key part in the development of Spravato (esketamine) and various other CNS medications.
Amy Emerson's Legacy and Transition
Amy Emerson leaves behind an impressive legacy after nearly ten years of leadership at Lykos. Since the company was founded in 2014, she has been a vital part of its mission to innovate treatments for mental health. Following her departure, Emerson will continue as a senior advisor and will remain engaged through her position on the Lykos Board. Reflecting on her time with the company, she remarked, "While we are not at the finish line, the past decade of progress has been monumental. Mike has been an outstanding partner and is well prepared to step in and lead our next steps."
The Vision for Mental Health Treatment
Lykos Therapeutics is dedicated to enhancing the treatment landscape for mental health conditions, with midomafetamine leading the way. The company's innovative strategy includes the use of MDMA-assisted therapy, aiming to offer effective solutions for individuals struggling with PTSD and other related conditions. Lykos was the first to conduct randomized, controlled clinical trials, establishing a foundation for future therapies.
About Lykos Therapeutics
Lykos Therapeutics is a public benefit corporation established by the Multidisciplinary Association for Psychedelic Studies (MAPS). The company leverages decades of research to investigate and develop psychedelics for therapeutic use, initially focusing on PTSD. Lykos aims to make a positive difference in mental healthcare through its innovative treatments and methodologies.
Frequently Asked Questions
Who is the new interim CEO of Lykos Therapeutics?
Michael Mullette has been appointed as the interim CEO of Lykos Therapeutics, succeeding Amy Emerson.
What role will Amy Emerson take after stepping down?
Amy Emerson will transition to a senior advisor role and remain an observer on the Lykos Board.
What is Dr. David Hough's new position at Lykos?
Dr. David Hough has been named the Chief Medical Officer and will oversee the clinical development program and regulatory activities.
What therapy is Lykos Therapeutics focusing on?
Lykos is focused on midomafetamine-assisted therapy as an innovative treatment for PTSD and has pioneered clinical trials in this area.
What is the mission of Lykos Therapeutics?
Lykos Therapeutics aims to transform mental healthcare by developing and applying evidence-based research into psychedelic treatments for mental health conditions.
